A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy.

@article{Fizazi2017ARD,
  title={A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy.},
  author={Karim S Fizazi and Albertas Ulys and Lisa Sengel\ov and Mette Moe and Sylvain Ladoire and Antoine Thiery-Vuillemin and Aude Fl{\'e}chon and Annalisa Guida and Joaquim Bellmunt and Miquel {\'A}ngel Climent and Simon Chowdhury and Herlinde Dumez and Magda Matou{\vs}kov{\'a} and Nicolas Penel and Sigita Liutkauskiene and L Stachurski and Cora N Sternberg and Fr{\'e}d{\'e}rique Baton and Nathalie Germann and Gedske Daugaard},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2017},
  volume={28 11},
  pages={2741-2746}
}
Background This phase II study was conducted to assess clinical efficacy of tasquinimod maintenance therapy in patients with metastatic castrate-resistant prostate cancer not progressing during first-line docetaxel-based therapy. Patients and methods Patients were randomly assigned (1 : 1) to receive tasquinimod (0.25-1.0 mg/day orally) or placebo. The primary end point was radiologic progression-free survival (rPFS); secondary efficacy end points included: overall survival (OS); PFS on next… CONTINUE READING